Intellectus Partners LLC Buys 182 Shares of Cencora, Inc. (NYSE:COR)

Intellectus Partners LLC raised its stake in Cencora, Inc. (NYSE:COR) by 6.3% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 3,058 shares of the company’s stock after purchasing an additional 182 shares during the period. Intellectus Partners LLC’s holdings in Cencora were worth $688,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. New Millennium Group LLC acquired a new position in Cencora during the 2nd quarter worth approximately $26,000. TFO Wealth Partners LLC acquired a new position in shares of Cencora during the first quarter worth approximately $30,000. MFA Wealth Advisors LLC bought a new position in shares of Cencora in the 2nd quarter worth $30,000. Concord Wealth Partners bought a new stake in Cencora during the 3rd quarter valued at $30,000. Finally, LRI Investments LLC acquired a new position in Cencora during the first quarter worth $31,000. Institutional investors own 97.52% of the company’s stock.

Analysts Set New Price Targets

COR has been the subject of several recent research reports. UBS Group boosted their target price on shares of Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th. JPMorgan Chase & Co. raised their target price on Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a report on Wednesday, August 21st. Robert W. Baird upped their price target on Cencora from $287.00 to $292.00 and gave the stock an “outperform” rating in a report on Thursday, November 7th. StockNews.com cut Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Barclays upped their target price on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $271.20.

Cencora Trading Down 1.1 %

Shares of COR stock opened at $240.24 on Friday. Cencora, Inc. has a 12-month low of $194.23 and a 12-month high of $251.56. The company has a quick ratio of 0.53, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The company has a 50 day moving average of $232.62 and a 200-day moving average of $231.08. The firm has a market cap of $47.34 billion, a P/E ratio of 31.99, a PEG ratio of 1.66 and a beta of 0.44.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, November 29th. Stockholders of record on Friday, November 15th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.92%. The ex-dividend date of this dividend is Friday, November 15th. This is a boost from Cencora’s previous quarterly dividend of $0.51. Cencora’s dividend payout ratio is currently 29.29%.

Insider Transactions at Cencora

In other Cencora news, Chairman Steven H. Collis sold 21,509 shares of the company’s stock in a transaction dated Tuesday, October 22nd. The shares were sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at $67,223,750.40. This represents a 7.02 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 15.80% of the stock is owned by corporate insiders.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.